Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint
ARGX•Phase 3 Alkivia trial met primary endpoint
Aug. 17 (Reuters) - argenx SE ARGX.BR:
- Argenx announces positive topline results from Phase 3 Alkivia trial of efgartigimod in autoimmune myositis
- Phase 3 study meets primary endpoint in IMNM and DM patients at week 52
- Efgartigimod demonstrates early and sustained improvement over placebo through one year
- Efgartigimod well-tolerated with consistent safety profile in Alkivia study
Related News
Bradesco names Armando Sposito Júnior, Luiz Renato Gonçalves de Lima, José Ricardo Paliares and Daniel Augusto Falbi as directors
BBD•
Visium Technologies withdraws Series G preferred stock designation after finding no shares were issued
VISM•
